MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2026.111550

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).

Wishart Laurelie R, O'Shea Julianne, Rischin Danny, Corry June, Dixon Benjamin J, O'Leary Stephen, Wilson Wayne J, Zahir Syeda Farah, Hanson Dominic, Smith Justin, Porceddu Sandro V

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

PURPOSE: Cisplatin-associated deterioration in sensorineural hearing thresholds is an important survivorship concern in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Weekly low-dose cisplatin may reduce ototoxicity compared with high-dose schedules, but randomized audiometric data are limited. This secondary analysis of TROG 12.01 compared hearing outcomes between weekly cisplatin + radiotherapy (RT) and cetuximab + RT.

METHODS

Audiometric data were available for 101 TROG 12.01 trial participants. Patients received 70 Gy in 35 fractions with either weekly cisplatin (40 mg/m2, n = 55) or cetuximab (400 mg/m2 loading, then 250 mg/m2 weekly, n = 46). Pure-tone audiometry (500-8000 Hz) was obtained at baseline and 12-months. Linear mixed-effects models assessed absolute change in air-conduction thresholds. Logistic regression identified predictors of clinically significant deterioration in sensorineural hearing thresholds. To evaluate radiation-specific effects, receiver-operating characteristic (ROC) analyses of cochlea dose were performed in the cetuximab + RT cohort.

RESULTS

Across 101 patients, 41% developed clinically significant deterioration in sensorineural hearing thresholds at 12-months: 45.5% with cisplatin + RT and 34.8% with cetuximab + RT. At 8000 Hz, cisplatin + RT was associated with greater deterioration (mean shift 6.83 dB; p = 0.01), remaining significant after multivariable adjustment (estimate 5.58 dB; p = 0.04). In the cetuximab + RT cohort, ROC analysis identified cochlea mean dose > 5.09 Gy (AUC 0.69) and maximum dose > 7.16 Gy (AUC 0.70) as cut-points associated with deterioration in sensorineural hearing thresholds.

CONCLUSION

Weekly low-dose cisplatin is associated with clinically significant deterioration in high-frequency hearing. Cochlea RT doses contributed independently to ototoxicity however dose-estimation thresholds require further validation. Findings highlight the value of audiologic monitoring and the relevance of cochlear dose in HPV-positive OPSCC treated with low-dose cisplatin, with implications for future prospective trials.

Для цитирования: Wishart Laurelie R, O'Shea Julianne, Rischin Danny, Corry June, Dixon Benjamin J, O'Leary Stephen, Wilson Wayne J, Zahir Syeda Farah, Hanson Dominic, Smith Justin, Porceddu Sandro V. Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2026. DOI: 10.1016/j.radonc.2026.111550.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.